Clinical trial Intelligence for contract research organizations
We help CROs win business and enhance drug development services. Make better-informed decisions while bidding on and implementing clinical trials.
There are some trials that could be great for your business and others that might not be. But without high-quality intelligence, it can be hard to assess or maximize a trial’s potential.
How we help
Our thorough and extensive clinical trial intelligence for CROs will help your organization:
We’ll help you identify companies active in your territory and their phases of development. Spot where to run trials, with our data on where comparator trials have been approved and the availability of regional investigators.
You can size up competing trials, because we monitor and benchmark them, prioritizing investigators and tracking enrollment. And to help you mitigate risks, we can provide intelligence on safety issues faced by trials of similar designs.
12 Aug 2019
Get a visual snapshot of how the industry pipelines are faring with our 2018 Completed Trials snapshot. This graphic analysis paints a clear picture of the state of clinical trial completions, while pointing to some important changes that are emerging.
06 Aug 2019
The landscape of trials initiated by industry sponsors is one metric that informs about the R&D health of the biopharma industry. Looking specifically at trial completions adds a layer of granularity to the trials landscape and provides valuable perspective on how well industry pipelines are faring. As Informa Pharma has done for the past four years, we report the results from our analysis of the landscape of clinical trials completed during 2018.
30 Jul 2019
KNect365 Life Sciences recently conducted a survey into the clinical trial industry at its most interesting point to date, as organisations are implementing new technologies and trends such as AI, virtual trials and wearables. The final report, based on 214 responses, reveals unique insights into what current benefits and challenges companies are facing in the processes of applying these new approaches to therapeutic development. Citeline introduces the report, exploring what some of the key takeaways mean for the industry.
03 Jul 2019
With opioid abuse and deaths in the US at an all-time high, the journey to battle the opioid epidemic continues – keeping drug companies and the FDA working hard to come up with effective alternatives for pain.
02 Jul 2019
For a snapshot of the new active substances (NAS) successfully launched last year, download the data-packed New Active Substances (NAS) Launched During 2018 infographic from Citeline.
02 Jul 2019
The discovery and deep investigation of the microbiome has been one of the most significant recent biomedical advances. Extensive research suggests that dysbiosis of the gut microbiome plays a significant role in multiple gastrointestinal (GI) disorders such as; Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS).
Citeline, Sitetrove, Trialtrove, Pharmaprojects
02 Jul 2019
Citeline is the industry’s most comprehensive, reliable and up-to-date global clinical trial intelligence suite, designed to help you save time and money by enrolling patients faster. Our team of more than 250 industry experts transform data into knowledge, integrating robust drug, trial, investigator, and site intelligence.
By Christine Blazynski, PhD 25 Jun 2019
The average cost of bringing a new drug to market continues to rise, with varying levels of investments across the highly competitive biopharmaceutical industry. To assess the potential effect of varying investments on trial activity and operations, this article reviews trial benchmarks within the active oncology therapeutic area. Industry-sponsored clinical trials across all oncology indications covered by Informa Pharma Intelligence’s Trialtrove were assessed, comparing metrics by company size based on pharma sales, and the identical benchmarks for breast cancer and rare cancers were also analyzed.
By Doro Shin 15 Jun 2019
For a detailed look at the statistics and trends surrounding clinical trials initiated in 2017, we invite you to download 2017 Clinical Trials Roundup: The Evolution Continues. Using a wealth of trial data from Trialtrove, this information-packed white paper provides a detailed analysis of Phase I–III clinical trials that were initiated last year.
Topic Clinical trials
11 Jun 2019
Find the right investigators and sites for your clinical trials. For the pharma industry’s most accurate and comprehensive investigator and site intelligence, turn to the invaluable data in Sitetrove. Sitetrove’s team of expert analysts continuously scour over 43,000 public sources to update curated information on the global clinical trial landscape, with content tailored to specific therapeutic areas. Save time and avoid costly delays: find the right investigators in the geographic areas that suit your needs with Sitetrove.
11 Jun 2019
Take the analysis from the Informa Pharma Intelligence R&D Annual Review 2019 further with the Pharma R&D Annual Review 2019 Supplement: New Active Substances Launched During 2018. This essential whitepaper uses critical data from Pharmaprojects to examine the new entities that were successfully launched to market last year.
By KNect365 11 Jun 2019
Clinical trials are continually evolving, particularly in light of increasing pressures from new technologies and other disruptors. Trends ranging from artificial intelligence (AI) and mHealth to patient-centricity are challenging the industry to innovate against the backdrop of looming regulatory changes and shifting competitor landscapes resulting from M&A activity. In order to explore these trends, KNect365 Life Sciences recently conducted one of the biggest surveys of its kind across clinical trial professionals from within pharma, CROs, sites, service providers, academia and patient groups across the world to look beyond the hype.
By Ian Lloyd 30 May 2019
Will the Pharma R&D Annual Review 2018 from Citeline’s Pharmaprojects be music to your ears, or will it sound a sour note? Find out with the Pharma R&D Annual Review 2018 infographic, now available to you as a free download.
By Ian Lloyd 30 May 2019
Pharma R&D Annual Review 2019 is based on the stats and data from from Pharmaprojects, part of Informa’s Citeline family of intelligence solutions. Authored for the 27th time by Ian Lloyd, Senior Director, Pharmaprojects.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: